Hermetica Superfood Encyclopedia
Legacy index-continuity record: the score and narrative are provisional and must not be represented as validated or human-approved.
Review flags: AWAITING_SEMANTIC_VALIDATION
Dipeptidyl Peptidase-4 (DPP-IV) is an enzyme that rapidly degrades incretin hormones, such as GLP-1, which are vital for glucose-dependent insulin secretion. Targeted inhibition of DPP-IV by oral antidiabetic drugs prolongs incretin activity, significantly enhancing insulin secretion and suppressing glucagon to improve glycemic control in type 2 diabetes.
Reported Benefits (Provisional)
Origin & History
Dipeptidyl Peptidase-4 (DPP-IV) is an enzyme found throughout the body in tissues such as the small intestine, liver, and kidneys, and is naturally occurring in humans and certain microbial and dietary sources. It plays a crucial role in regulating blood sugar by degrading incretin hormones and also aids in the digestion of proline-rich peptides found in gluten and casein. Its multifaceted action makes it significant for metabolic health and protein digestion.
Research Narrative (Provisional)
DPP-IV is supported by extensive research on its role in incretin metabolism, immune modulation, and protein digestion. DPP-IV inhibition is clinically validated as an effective strategy for glycemic control in type 2 diabetes.
Preparation & Dosage
Dosage guidance is withheld because the publication gate has not recorded adequate support for this profile.
Nutritional Profile
- Incretin Hormone Regulation: Degrades GLP-1 and GIP, which are responsible for enhancing insulin secretion and suppressing glucagon. - Protein Digestion: Facilitates breakdown of peptides with proline residues, aiding in the digestion of gluten and dairy proteins. - Immune Response: Involved in immune signaling, influencing inflammation and tolerance.
Reported Mechanism (Provisional)
Dipeptidyl Peptidase-4 (DPP-IV) is a membrane-bound enzyme primarily responsible for the rapid degradation of incretin hormones, specifically glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). DPP-IV inhibitors (e.g., sitagliptin, saxagliptin, linagliptin, alogliptin) competitively block this enzyme, leading to a 2-3-fold increase in endogenous active GLP-1 levels. This prolonged incretin activity enhances glucose-dependent insulin secretion from pancreatic beta cells and suppresses glucagon release from alpha cells, thereby improving postprandial glycemic control without a significant intrinsic risk of hypoglycemia.
Clinical Narrative (Provisional)
DPP-IV inhibition is a clinically validated and effective strategy for glycemic control in type 2 diabetes, supported by extensive research on its role in incretin metabolism. Numerous clinical studies have demonstrated that DPP-IV inhibitors consistently improve key glycemic parameters, including HbA1c and postprandial glucose levels, in patients with type 2 diabetes. These studies show that the prolongation of incretin hormone effects leads to enhanced insulin secretion and modulated glucagon activity, contributing to better overall blood sugar regulation and often with a favorable safety profile regarding hypoglycemia.
Also Known As
Research updates — and 25% off your first order
Join our list for source-aware wellness education, review-state updates, and product news — and unlock 25% off your first Hermetica order. Educational content is not medical advice. No spam, unsubscribe anytime.